AbbVie Expects Negative Q2 Impact Due to IPR&D and Milestones Expense of $823M

AbbVie expects a negative impact of $0.42 to GAAP and non-GAAP diluted earnings per share in Q2 due to a $823M acquired IPR&D and milestones expense. This will result in a negative impact on Q2 adjusted diluted earnings per share. The company also sees a full-year impact from the expense.